The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: A prospective study

被引:48
作者
Grob, JJ
Richard, MA
Gouvernet, J
Avril, MF
Delaunay, M
Wolkenstein, P
Souteyrand, P
Bonerandi, JJ
Machet, L
Guillaume, JC
Chevrant-Breton, J
Vilmer, C
Aubin, F
Guillot, B
Beylot-Barry, M
Lok, C
Raison-Peyron, N
Chemaly, P
机构
[1] Univ Mediterranee, Serv Dermatol, Fac Med, Hop St Marguerite, F-13009 Marseille, France
[2] Hop Enfants La Timone, Serv Informat Med, F-13385 Marseille, France
[3] Inst Gustave Roussy, Serv Dermatol, F-94805 Villejuif, France
[4] Hop Pellegrin, Serv Dermatol, F-33076 Bordeaux, France
[5] Hop Henri Mondor, Serv Dermatol, F-94010 Creteil, France
[6] Hop Hotel Dieu, Serv Dermatol, Clermont Ferrand, France
[7] Hop Enfants La Timone, Serv Dermatol, F-13385 Marseille, France
[8] Hop Trousseau, Serv Dermatol, Tours, France
[9] Hop Louis Pasteur, Serv Dermatol, Colmar, France
[10] Hop Hotel Dieu, Serv Dermatol, Rennes, France
[11] Ctr Rene Huguenin, Serv Dermatol, St Cloud, France
[12] Hop St Jacques, Serv Dermatol, F-25030 Besancon, France
[13] Hop Caremeau, Serv Dermatol, Nimes, France
[14] Hop Haut Leveque, Serv Dermatol, Pessac, France
[15] Hop Sud, Serv Dermatol, Amiens, France
[16] Hop St Charles, Serv Dermatol, Montpellier, France
[17] Hop St Louis, Serv Anat & Cytol Pathol, Paris, France
关键词
melanoma; kinetics; prognosis;
D O I
10.1002/ijc.10660
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary melanoma (MM) could be a good model to test an intuitive concept: a cancer that is growing fast in its early phase is likely to have a high aggressiveness. Since MMs are visible tumors, many patients can provide information to indirectly assess the kinetics of their lesion. A prospective study was designed to assess if the kinetics of the visible growth of a primary MM, as described by the patient, could be a noninvasive prognostic marker. The ratio of MM thickness to delay between MM appearance and MM removal was used as a surrogate value for the kinetics of the MM growth. To assess the delay between MM appearance and removal, 362 patients with self-detected invasive MM fulfilled a detailed questionnaire, which provided 2 types of estimations of this delay and thus 2 melanoma kinetics indexes (MKI and MKI*). After a median follow-up of 4 years, univariate and multivariate analyses assessed whether relapse-free survival was linked to MKI or MKI*. MKI was significantly predictive of relapse-free survival (HR = 1.84 [1.51-2.25]) and relapse at I year (RR = 2.93 [1.84-4.69]), independently from Breslow thickness. MKI was retained in multivariate prognostic models, just after thickness and before other usual markers. MKI* was also a significant independent risk marker, although less predictive. In this model, the initial growth kinetics of a cancer reflects its aggressiveness and a high index predicts a short-term relapse. The "subjective" data obtained from patients about their MM history, although usually neglected, can thus provide a better prognostic marker than many "objective" tests. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 13 条
[1]  
[Anonymous], 1995, ANN DERMATOL VENEREO, V122, P250
[2]   Rapid and unbiased estimation of the volume of cutaneous malignant melanoma using Cavalieri's principle [J].
Bahmer, FA ;
Hantirah, S ;
Baum, HP .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1996, 18 (02) :159-164
[3]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[4]   Serological markers for melanoma [J].
Brochez, L ;
Naeyaert, JM .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (02) :256-268
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   Melastatin expression and prognosis in cutaneous malignant melanoma [J].
Duncan, LM ;
Deeds, J ;
Cronin, FE ;
Donovan, M ;
Sober, AJ ;
Kauffman, M ;
McCarty, JJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :568-576
[7]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[8]   Narrative based medicine - Narrative based medicine in an evidence based world [J].
Greenhalgh, T .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7179) :323-325
[9]   Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma [J].
Mårtenson, ED ;
Hansson, LO ;
Nilsson, B ;
von Schoultz, E ;
Brahme, EM ;
Ringborg, U ;
Hansson, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :824-831
[10]   Melanoma thickness and histology predict sentinel lymph node status [J].
Nguyen, CL ;
McClay, EF ;
Cole, DJ ;
O'Brien, PH ;
Gillanders, WE ;
Metcalf, JS ;
Maize, JC ;
Baron, PL .
AMERICAN JOURNAL OF SURGERY, 2001, 181 (01) :8-11